JULY 202419TECH OUTLOOKEqually important is its exclusively U.S.-based process development, pre-clinical, clinical and commercial manufacturing network in Bristol, PA and San Diego, CA, which maintains compliance and offers a secure and IP-protected environment for biopharmaceutical companies to protect their inventions and innovations while scaling up their program. This also aligns with the FDA's responsiveness to submissions from US-based manufacturers, minimizing delays in the IND and biologic license application (BLA) submission processes."When we think about a true end-to-end integrated offering, it doesn't just involve process development, analytical development, and manufacturing. It's the execution of all those things, plus the ability to assemble them in a comprehensive package for the regulators. Our in-house regulatory services team helps customers to do just that. And in the small to medium-sized biotech world, we can add value as an end-to-end partner," shares Stober. "Supporting everything from R&D, all the way through to commercial manufacturing is something that we feel is unique in the industry, where we offer all of those different services and work as an integrated part of our customers' organization."Substantiating its impact is a success story where Abzena helped a small, four-person biopharmaceutical company spark a transformation. In this instance, the company provided strategic guidance, scientific expertise, and resource support to help their customer achieve clinical milestones. Abzena's expertise in cutting-edge ADC programs ensured clinical success and propelled the customer's ADC oncology product to Phase III.Ultimately, the biopharma customer expanded to become a robust 150-person, post-initial public offering (IPO) entity, marking their success in opening up ADCs in the field of rare diseases. This journey perfectly captures the evolution of an idea from a small team to a state-of-the-art cancer treatment that can change millions of lives. Aspiring to be a catalyst for transformative changes, Abzena is focused on driving pioneering scientific initiatives.Its ability to provide end-to-end solutions, from discovery to commercial manufacturing, positions it as a reliable partner for customers seeking a seamless and efficient journey through the complex biopharmaceutical landscape. Understanding and mitigating customer challenges with radical science and technologies, it emerges as a trustworthy ally. Abzena's strong and holistic competencies, combined with the surge in venture capital funding across the biotech market, position it as a pivotal player, equipping organizations with vast expertise and holistic guidance. We holistically support our customers, turning their idea or sequence into a marketable product by fortifying crucial tasks like clinical research, investigational new drug (IND) submissions, and final product development activities
< Page 9 | Page 11 >